Mizuho raises Boston Scientific target to $130, maintains Outperform
Securities adjusted its outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $130 from $110 while maintaining an Outperform rating. The revision follows a series of positive developments reported by the medical device company,
Boston Scientific price target raised to $122 from $119 at Raymond James
Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating
Boston Scientific (NYSE:BSX) Price Target Raised to $115.00
Boston Scientific (NYSE:BSX – Free Report) had its price objective raised by Piper Sandler from $95.00 to $115.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.
Truist lifts Boston Scientific stock target to $120, maintains Buy
Truist Securities expressed a positive outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $120 from $110, while reaffirming a Buy rating. The stock, currently trading near its 52-week high of $107.
Boston Scientific price target raised to $120 from $110 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific (BSX) to $120 from $110 and keeps a Buy rating on the
Boston Scientific sees higher-than-expected 2025 profit on strong demand
Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices. Manufacturers of medical devices have been benefiting from the elevated demand for elective surgical procedures in the United States,
Boston Scientific closes its year of PFA on a high note
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
American Association of Individual Investors21h
Which Is a Better Investment, Boston Scientific Corporation or Penumbra, Inc. Stock?
Learn more about whether Boston Scientific Corporation or Penumbra, Inc. is a better investment based on AAII's A+ Investor ...
MassDevice1d
Boston Scientific expects double-digit sales growth in 2025 following Street-beating Q4
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
BioWorld16h
Boston Sci’s Farapulse tops $1B in 2024, bright prospects for 2025
As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the ...
Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...
Boston Scientific 4Q Profit Up on Strong Cardio Device Sales
Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...
Boston Scientific remains bullish despite tariffs with sales buoyed by Minnesota tech
Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...
Boston Scientific targets 12%-14% EPS growth for 2025 with strong FARAPULSE and WATCHMAN momentum
Q4 2024 Management View CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in ...